Mesoblast Limited
Ryoncil
steroid-refractory acute graft versus host disease (SR-aGvHD)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on Ryoncil for steroid-refractory acute graft versus host disease (SR-aGvHD) is expected Date TBD.
Primary source
· SEC 6-K
verified 13h ago
“Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy.”